Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2014

Open Access 01-12-2014 | Original investigation

Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance

Authors: Tingting Du, Gang Yuan, Muxun Zhang, Xinrong Zhou, Xingxing Sun, Xuefeng Yu

Published in: Cardiovascular Diabetology | Issue 1/2014

Login to get access

Abstract

Background

To directly compare traditional lipid ratios (total cholesterol [TC]/high density lipoprotein cholesterol [HDL-C], non-HDL-C/HDL-C, low density lipoprotein cholesterol [LDL-C]/HDL-C, and triglycerides [TG]/HDL-C), apolipoprotein B (apoB)/apolipoprotein A-I (apoA-I) ratio, visceral adiposity index (VAI), lipid accumulation product (LAP), and the product of TG and fasting glucose (TyG) for strength and independence as risk factors for insulin resistance (IR).

Methods

We conducted a cross-sectional analysis of 7629 Chinese adults using data from the China Health and Nutrition Survey 2009.

Results

For all lipid ratios (traditional lipid ratios and apoB/apoA-I), among both sexes, TG/HDL-C explained the most additional percentage of variation in HOMA-IR (2.9% in men, and 2.3% in women); for all variables of interest, the variability in HOMA-IR explained by VAI and TG/HDL-C were comparable; TyG had the most significant association with HOMA-IR, which explained 9.1% for men and 7.8% for women of the variability in HOMA-IR. Logistic regression analysis showed the similar patterns. Receiver operating characteristic (ROC) curve analysis showed that, among both sexes, TG/HDL-C was a better discriminator of IR than apoB/apoA-I; the area under the ROC curve (AUC) for VAI (0.695 in men and 0.682 in women) was greater than that for TG/HDL-C (AUC 0.665 in men and 0.664 in women); TyG presented the greatest value of AUC (0.709 in men and 0.711 in women).

Conclusion

The apoB/apoA-I performs no better than any of the traditional lipid ratios in correlating with IR. The TG/HDL-C, VAI and TyG are better markers for early identification of IR individuals.
Literature
1.
go back to reference Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993, 329: 1988-1992. 10.1056/NEJM199312303292703.CrossRefPubMed Lillioja S, Mott DM, Spraul M, Ferraro R, Foley JE, Ravussin E, Knowler WC, Bennett PH, Bogardus C: Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med. 1993, 329: 1988-1992. 10.1056/NEJM199312303292703.CrossRefPubMed
2.
go back to reference Kimm H, Lee SW, Lee HS, Shim KW, Cho CY, Yun JE, Jee SH: Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin. - Usefulness of lipid ratios in Korean men and women. Circ J. 2010, 74: 931-937. 10.1253/circj.CJ-09-0571.CrossRefPubMed Kimm H, Lee SW, Lee HS, Shim KW, Cho CY, Yun JE, Jee SH: Associations between lipid measures and metabolic syndrome, insulin resistance and adiponectin. - Usefulness of lipid ratios in Korean men and women. Circ J. 2010, 74: 931-937. 10.1253/circj.CJ-09-0571.CrossRefPubMed
3.
go back to reference Despres JP: Is visceral obesity the cause of the metabolic syndrome?. Ann Med. 2006, 38: 52-63. 10.1080/07853890500383895.CrossRefPubMed Despres JP: Is visceral obesity the cause of the metabolic syndrome?. Ann Med. 2006, 38: 52-63. 10.1080/07853890500383895.CrossRefPubMed
4.
go back to reference Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999, 83: 25F-29F. 10.1016/S0002-9149(99)00211-8.CrossRefPubMed Grundy SM: Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999, 83: 25F-29F. 10.1016/S0002-9149(99)00211-8.CrossRefPubMed
5.
go back to reference DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991, 14: 173-194. 10.2337/diacare.14.3.173.CrossRefPubMed DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991, 14: 173-194. 10.2337/diacare.14.3.173.CrossRefPubMed
6.
go back to reference Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, Hellenius ML, Fisher RM: ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007, 28: 2637-2643. 10.1093/eurheartj/ehm360.CrossRefPubMed Sierra-Johnson J, Romero-Corral A, Somers VK, Lopez-Jimenez F, Walldius G, Hamsten A, Hellenius ML, Fisher RM: ApoB/apoA-I ratio: an independent predictor of insulin resistance in US non-diabetic subjects. Eur Heart J. 2007, 28: 2637-2643. 10.1093/eurheartj/ehm360.CrossRefPubMed
7.
go back to reference Davidson MH: Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol. 2008, 28: 1582-1583. 10.1161/ATVBAHA.108.172718.CrossRefPubMed Davidson MH: Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment. Arterioscler Thromb Vasc Biol. 2008, 28: 1582-1583. 10.1161/ATVBAHA.108.172718.CrossRefPubMed
8.
go back to reference Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC: Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia. 2010, 53: 1846-1855. 10.1007/s00125-010-1806-9.CrossRefPubMed Taskinen MR, Barter PJ, Ehnholm C, Sullivan DR, Mann K, Simes J, Best JD, Hamwood S, Keech AC: Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia. 2010, 53: 1846-1855. 10.1007/s00125-010-1806-9.CrossRefPubMed
9.
go back to reference Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008, 29: 2959-2971. 10.1093/eurheartj/ehn387.CrossRefPubMed Hajer GR, van Haeften TW, Visseren FL: Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. 2008, 29: 2959-2971. 10.1093/eurheartj/ehn387.CrossRefPubMed
10.
go back to reference Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E: Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab. 2002, 87: 5098-5103. 10.1210/jc.2002-020696.CrossRefPubMed Gastaldelli A, Miyazaki Y, Pettiti M, Matsuda M, Mahankali S, Santini E, DeFronzo RA, Ferrannini E: Metabolic effects of visceral fat accumulation in type 2 diabetes. J Clin Endocrinol Metab. 2002, 87: 5098-5103. 10.1210/jc.2002-020696.CrossRefPubMed
11.
go back to reference Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study G: Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010, 33: 920-922. 10.2337/dc09-1825.PubMedCentralCrossRefPubMed Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S, Midiri M, Galluzzo A, AlkaMeSy Study G: Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010, 33: 920-922. 10.2337/dc09-1825.PubMedCentralCrossRefPubMed
12.
go back to reference Kahn HS: The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005, 5: 26-10.1186/1471-2261-5-26.PubMedCentralCrossRefPubMed Kahn HS: The "lipid accumulation product" performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005, 5: 26-10.1186/1471-2261-5-26.PubMedCentralCrossRefPubMed
13.
go back to reference Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA: Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012, 308: 1150-1159. 10.1001/2012.jama.11132.PubMedCentralCrossRefPubMed Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA: Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012, 308: 1150-1159. 10.1001/2012.jama.11132.PubMedCentralCrossRefPubMed
14.
go back to reference Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, Jacques-Camarena O, Rodriguez-Moran M: The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010, 95: 3347-3351. 10.1210/jc.2010-0288.CrossRefPubMed Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez-Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, Jacques-Camarena O, Rodriguez-Moran M: The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010, 95: 3347-3351. 10.1210/jc.2010-0288.CrossRefPubMed
15.
go back to reference Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F: The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008, 6: 299-304. 10.1089/met.2008.0034.CrossRefPubMed Simental-Mendia LE, Rodriguez-Moran M, Guerrero-Romero F: The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008, 6: 299-304. 10.1089/met.2008.0034.CrossRefPubMed
16.
go back to reference Taniguchi A, Nakai Y, Sakai M, Yoshii S, Hamanaka D, Hatae Y, Kawata M, Yamanouchi K, Okumura T, Doi K, Tokuyama K, Nagasaka S, Fukushima M: Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. Metabolism. 2002, 51: 544-548. 10.1053/meta.2002.31984.CrossRefPubMed Taniguchi A, Nakai Y, Sakai M, Yoshii S, Hamanaka D, Hatae Y, Kawata M, Yamanouchi K, Okumura T, Doi K, Tokuyama K, Nagasaka S, Fukushima M: Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients. Metabolism. 2002, 51: 544-548. 10.1053/meta.2002.31984.CrossRefPubMed
17.
go back to reference Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, Nagasaka S, Doi K, Okumura T, Fukuda A, Kishimoto H, Fukuda T, Nakaishi S, Tokuyama K, Nakai Y: Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care. 2000, 23: 1766-1769. 10.2337/diacare.23.12.1766.CrossRefPubMed Taniguchi A, Fukushima M, Sakai M, Miwa K, Makita T, Nagata I, Nagasaka S, Doi K, Okumura T, Fukuda A, Kishimoto H, Fukuda T, Nakaishi S, Tokuyama K, Nakai Y: Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients. Diabetes Care. 2000, 23: 1766-1769. 10.2337/diacare.23.12.1766.CrossRefPubMed
18.
go back to reference Popkin BM, Du S, Zhai F, Zhang B: Cohort Profile: The China Health and Nutrition Survey-monitoring and understanding socio-economic and health change in China, 1989-2011. Int J Epidemiol. 2010, 39: 1435-1440. 10.1093/ije/dyp322.PubMedCentralCrossRefPubMed Popkin BM, Du S, Zhai F, Zhang B: Cohort Profile: The China Health and Nutrition Survey-monitoring and understanding socio-economic and health change in China, 1989-2011. Int J Epidemiol. 2010, 39: 1435-1440. 10.1093/ije/dyp322.PubMedCentralCrossRefPubMed
19.
go back to reference Alberti KG, Zimmet P, Shaw J: Group IDFETFC: The metabolic syndrome'a new worldwide definition. Lancet. 2005, 366: 1059-1062. 10.1016/S0140-6736(05)67402-8.CrossRefPubMed Alberti KG, Zimmet P, Shaw J: Group IDFETFC: The metabolic syndrome'a new worldwide definition. Lancet. 2005, 366: 1059-1062. 10.1016/S0140-6736(05)67402-8.CrossRefPubMed
20.
go back to reference Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002, 106: 3143-3421.
21.
go back to reference Zhang ZQ, He LP, Xie XY, Ling WH, Deng J, Su YX, Chen YM: Association of simple anthropometric indices and body fat with early atherosclerosis and lipid profiles in Chinese adults. PLoS One. 2014, 9: e104361-10.1371/journal.pone.0104361.PubMedCentralCrossRefPubMed Zhang ZQ, He LP, Xie XY, Ling WH, Deng J, Su YX, Chen YM: Association of simple anthropometric indices and body fat with early atherosclerosis and lipid profiles in Chinese adults. PLoS One. 2014, 9: e104361-10.1371/journal.pone.0104361.PubMedCentralCrossRefPubMed
22.
go back to reference Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001, 358: 2026-2033. 10.1016/S0140-6736(01)07098-2.CrossRefPubMed Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E: High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001, 358: 2026-2033. 10.1016/S0140-6736(01)07098-2.CrossRefPubMed
23.
go back to reference McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008, 372: 224-233. 10.1016/S0140-6736(08)61076-4.CrossRefPubMed McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, Kazmi K, Yusuf S: Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008, 372: 224-233. 10.1016/S0140-6736(08)61076-4.CrossRefPubMed
24.
go back to reference van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT: Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. 2007, 146: 640-648. 10.7326/0003-4819-146-9-200705010-00007.CrossRefPubMed van der Steeg WA, Boekholdt SM, Stein EA, El-Harchaoui K, Stroes ES, Sandhu MS, Wareham NJ, Jukema JW, Luben R, Zwinderman AH, Kastelein JJ, Khaw KT: Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med. 2007, 146: 640-648. 10.7326/0003-4819-146-9-200705010-00007.CrossRefPubMed
25.
go back to reference Hermans MP, Ahn SA, Rousseau MF: Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM. Cardiovasc Diabetol. 2013, 12: 39-10.1186/1475-2840-12-39.PubMedCentralCrossRefPubMed Hermans MP, Ahn SA, Rousseau MF: Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM. Cardiovasc Diabetol. 2013, 12: 39-10.1186/1475-2840-12-39.PubMedCentralCrossRefPubMed
26.
go back to reference Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Kadota A, Kadowaki S, Kadowaki T, Yamamoto T, Miyagawa N, Zaid M, Torii S, Takashima N, Murakami Y, Okamura T, Horie M, Ueshima H: Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population. Atherosclerosis. 2014, 236: 237-243. 10.1016/j.atherosclerosis.2014.07.019.CrossRefPubMed Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Kadota A, Kadowaki S, Kadowaki T, Yamamoto T, Miyagawa N, Zaid M, Torii S, Takashima N, Murakami Y, Okamura T, Horie M, Ueshima H: Lipoprotein particle profiles compared with standard lipids in association with coronary artery calcification in the general Japanese population. Atherosclerosis. 2014, 236: 237-243. 10.1016/j.atherosclerosis.2014.07.019.CrossRefPubMed
27.
go back to reference McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003, 139: 802-809. 10.7326/0003-4819-139-10-200311180-00007.CrossRefPubMed McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med. 2003, 139: 802-809. 10.7326/0003-4819-139-10-200311180-00007.CrossRefPubMed
28.
go back to reference McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM: Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol. 2005, 96: 399-404. 10.1016/j.amjcard.2005.03.085.CrossRefPubMed McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM: Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease?. Am J Cardiol. 2005, 96: 399-404. 10.1016/j.amjcard.2005.03.085.CrossRefPubMed
29.
go back to reference Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ: Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol. 2008, 101: 497-501. 10.1016/j.amjcard.2007.09.109.PubMedCentralCrossRefPubMed Kannel WB, Vasan RS, Keyes MJ, Sullivan LM, Robins SJ: Usefulness of the triglyceride-high-density lipoprotein versus the cholesterol-high-density lipoprotein ratio for predicting insulin resistance and cardiometabolic risk (from the Framingham Offspring Cohort). Am J Cardiol. 2008, 101: 497-501. 10.1016/j.amjcard.2007.09.109.PubMedCentralCrossRefPubMed
30.
go back to reference Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M: Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism. 2010, 59: 299-304. 10.1016/j.metabol.2009.07.027.CrossRefPubMed Kim-Dorner SJ, Deuster PA, Zeno SA, Remaley AT, Poth M: Should triglycerides and the triglycerides to high-density lipoprotein cholesterol ratio be used as surrogates for insulin resistance?. Metabolism. 2010, 59: 299-304. 10.1016/j.metabol.2009.07.027.CrossRefPubMed
31.
go back to reference Stein E, Kushner H, Gidding S, Falkner B: Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome. Metabolism. 2007, 56: 954-960. 10.1016/j.metabol.2007.02.008.PubMedCentralCrossRefPubMed Stein E, Kushner H, Gidding S, Falkner B: Plasma lipid concentrations in nondiabetic African American adults: associations with insulin resistance and the metabolic syndrome. Metabolism. 2007, 56: 954-960. 10.1016/j.metabol.2007.02.008.PubMedCentralCrossRefPubMed
32.
go back to reference Leanca CC, Nunes VS, Panzoldo NB, Zago VS, Parra ES, Cazita PM, Jauhiainen M, Passarelli M, Nakandakare ER, de Faria EC, Quintao EC: Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects. Cardiovasc Diabetol. 2013, 12: 173-10.1186/1475-2840-12-173.PubMedCentralCrossRefPubMed Leanca CC, Nunes VS, Panzoldo NB, Zago VS, Parra ES, Cazita PM, Jauhiainen M, Passarelli M, Nakandakare ER, de Faria EC, Quintao EC: Metabolism of plasma cholesterol and lipoprotein parameters are related to a higher degree of insulin sensitivity in high HDL-C healthy normal weight subjects. Cardiovasc Diabetol. 2013, 12: 173-10.1186/1475-2840-12-173.PubMedCentralCrossRefPubMed
33.
go back to reference Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF: Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res. 2008, 103: 159-166. 10.1161/CIRCRESAHA.108.178756.CrossRefPubMed Xiao C, Watanabe T, Zhang Y, Trigatti B, Szeto L, Connelly PW, Marcovina S, Vaisar T, Heinecke JW, Lewis GF: Enhanced cellular uptake of remnant high-density lipoprotein particles: a mechanism for high-density lipoprotein lowering in insulin resistance and hypertriglyceridemia. Circ Res. 2008, 103: 159-166. 10.1161/CIRCRESAHA.108.178756.CrossRefPubMed
34.
go back to reference Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002, 23: 201-229. 10.1210/edrv.23.2.0461.CrossRefPubMed Lewis GF, Carpentier A, Adeli K, Giacca A: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev. 2002, 23: 201-229. 10.1210/edrv.23.2.0461.CrossRefPubMed
35.
go back to reference Tan CY, Vidal-Puig A: Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans. 2008, 36: 935-940. 10.1042/BST0360935.CrossRefPubMed Tan CY, Vidal-Puig A: Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans. 2008, 36: 935-940. 10.1042/BST0360935.CrossRefPubMed
36.
go back to reference Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008, 168: 1609-1616. 10.1001/archinte.168.15.1609.CrossRefPubMed Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, Rittig K, Balletshofer B, Machicao F, Fritsche A, Haring HU: Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008, 168: 1609-1616. 10.1001/archinte.168.15.1609.CrossRefPubMed
37.
go back to reference Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Kinoshita H, Ohkura H, Kato M, Taniguchi S, Yamamoto K: 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013, 12: 21-10.1186/1475-2840-12-21.PubMedCentralCrossRefPubMed Ohkura T, Shiochi H, Fujioka Y, Sumi K, Yamamoto N, Matsuzawa K, Izawa S, Kinoshita H, Ohkura H, Kato M, Taniguchi S, Yamamoto K: 20/(fasting C-peptide x fasting plasma glucose) is a simple and effective index of insulin resistance in patients with type 2 diabetes mellitus: a preliminary report. Cardiovasc Diabetol. 2013, 12: 21-10.1186/1475-2840-12-21.PubMedCentralCrossRefPubMed
38.
go back to reference Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000, 23: 57-63. 10.2337/diacare.23.1.57.CrossRefPubMed Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MB, Monauni T, Muggeo M: Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000, 23: 57-63. 10.2337/diacare.23.1.57.CrossRefPubMed
39.
go back to reference Sanchez-Quesada JL, Vinagre I, De Juan-Franco E, Sanchez-Hernandez J, Bonet-Marques R, Blanco-Vaca F, Ordonez-Llanos J, Perez A: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol. 2013, 12: 112-10.1186/1475-2840-12-112.PubMedCentralCrossRefPubMed Sanchez-Quesada JL, Vinagre I, De Juan-Franco E, Sanchez-Hernandez J, Bonet-Marques R, Blanco-Vaca F, Ordonez-Llanos J, Perez A: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovasc Diabetol. 2013, 12: 112-10.1186/1475-2840-12-112.PubMedCentralCrossRefPubMed
40.
go back to reference Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004, 27: 1496-1504. 10.2337/diacare.27.6.1496.CrossRefPubMed Krauss RM: Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004, 27: 1496-1504. 10.2337/diacare.27.6.1496.CrossRefPubMed
Metadata
Title
Clinical usefulness of lipid ratios, visceral adiposity indicators, and the triglycerides and glucose index as risk markers of insulin resistance
Authors
Tingting Du
Gang Yuan
Muxun Zhang
Xinrong Zhou
Xingxing Sun
Xuefeng Yu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2014
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-014-0146-3

Other articles of this Issue 1/2014

Cardiovascular Diabetology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.